Correction: Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates
- PMID: 38212405
- PMCID: PMC11257951
- DOI: 10.1038/s41434-023-00438-6
Correction: Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates
Erratum for
-
Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates.Gene Ther. 2024 May;31(5-6):224-233. doi: 10.1038/s41434-023-00410-4. Epub 2023 Aug 17. Gene Ther. 2024. PMID: 37587230 Free PMC article.
Similar articles
-
HIV-2 and SIV vector systems.Somat Cell Mol Genet. 2001 Nov;26(1-6):83-98. doi: 10.1023/a:1021026730034. Somat Cell Mol Genet. 2001. PMID: 12465463 Review.
-
African non human primates infected by SIV - why don't they get sick? Lessons from studies on the early phase of non-pathogenic SIV infection.Curr HIV Res. 2009 Jan;7(1):39-50. doi: 10.2174/157016209787048546. Curr HIV Res. 2009. PMID: 19149553 Review.
-
Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.Clin Vaccine Immunol. 2012 May;19(5):629-37. doi: 10.1128/CVI.00010-12. Epub 2012 Mar 21. Clin Vaccine Immunol. 2012. PMID: 22441384 Free PMC article.
-
In Vitro Validation of a CRISPR-Mediated CFTR Correction Strategy for Preclinical Translation in Pigs.Hum Gene Ther. 2019 Sep;30(9):1101-1116. doi: 10.1089/hum.2019.074. Epub 2019 Jun 18. Hum Gene Ther. 2019. PMID: 31099266
-
Mutations in CCR5-coding sequences are not associated with SIV carrier status in African nonhuman primates.AIDS Res Hum Retroviruses. 1999 Jul 1;15(10):931-9. doi: 10.1089/088922299310647. AIDS Res Hum Retroviruses. 1999. PMID: 10408730
Publication types
LinkOut - more resources
Full Text Sources